Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea
Incannex Healthcare announced the grant of a U.S. patent covering its proprietary oral combination therapy, IHL-42X, for obstructive sleep apnea (OSA). This patent extends protection of the treatment until 2040 and positions the company to potentially extend exclusivity post-FDA approval. The milestone complements recent FDA Fast Track designation …